New cell therapy HBI0101 targets Hard-to-Treat multiple myeloma in early trial
NCT ID NCT07333430
First seen Jan 12, 2026 · Last updated Jun 12, 2026 · Updated 21 times
Summary
This early-phase study tests a new cell therapy called HBI0101 CART in 60 adults with multiple myeloma that has returned or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to attack cancer cells. The main goals are to find the safest dose and check for side effects, while also seeing if the treatment can shrink the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA(MM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hadassah MO, Jerusalem, 9574869
RECRUITINGJerusalem, Israel
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.